The United States is tying payments for COVID-19 vaccines to timing milestones for production and approval, according to public documents and a Trump administration official, putting pressure on drugmakers including Moderna Inc (MRNA.O) to meet ambitious targets.
In a deal with Moderna announced this week, federal agencies negotiated a sliding scale of payments. The Cambridge, Massachusetts, biotech’s $1.5-billion deal pays out in full if its vaccine receives regulatory clearance by January 31, 2021, according to filings. It receives $1.2 billion, if it falls short of that timing goal.
Moderna also receives $600 million when it can demonstrate it has built out industrial-scale manufacturing capabilities for its vaccine, even if that happens before the drug is authorized by regulators, the filings show.
TVNL Comment: Money talks. Billions of dollars talk very loudly. Be ready for an untested, very possibly unsafe, and surely premature vaccine.
More...
With subsidies for Affordable Care Act (ACA) health insurance set to expire, Americans who rely on...
Connecticut, Georgia, Idaho, Massachusetts, Michigan, Rhode Island, South Carolina, Texas and Puerto Rico also saw an...
A California jury on Friday awarded $40m to two women who said Johnson & Johnson’s baby...
